# Treatment for Endogenous Cushing's Syndrome

> **NCT01838551** · PHASE3 · COMPLETED · sponsor: **Cortendo AB** · enrollment: 94 (actual)

## Conditions studied

- Endogenous Cushing's Syndrome

## Interventions

- **DRUG:** Levoketoconazole

## Key facts

- **NCT ID:** NCT01838551
- **Lead sponsor:** Cortendo AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2018-04
- **Final completion:** 2018-11
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2021-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01838551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01838551, "Treatment for Endogenous Cushing's Syndrome". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT01838551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*